A series of blood tests, procedures, and imaging tests can help diagnose acute myeloid leukemia (AML). Additionally, these tests can also determine its subtype and help identify the best treatment ...
A study highlights an unmet need for patients with acute myeloid leukemia (AML) to access and afford genomic testing, especially among an older patient population. In a real-world setting of new and ...
Errata: Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis The classification of AML and therapeutic options are now largely driven ...
Molecular testing is crucial for precision oncology in AML and MDS, but barriers hinder its routine integration. The study analyzed genomic data from 2018 to 2023, focusing on testing rates, types, ...
AML is an aggressive hematologic malignancy where molecular characterization can be time-sensitive in research settings for operational workflow and investigational assessment. The oncoReveal Rapid ...
SAN DIEGO — A polygenic score can link outcomes in Black pediatric patients with acute myeloid leukemia (AML) to genetic traits that arise more frequently in this population, new data reveal. The ...
Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription.
A small portion of adults in remission from a deadly blood cancer had persisting mutations that were detected, which predicted their risk of death from having the cancer return About 20,000 adults in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results